2. This new and seemingly overreaching request for
Post# of 148185
(Total Views: 643)
Posted On: 07/15/2020 4:03:44 PM
Quote:
2. This new and seemingly overreaching request for Mono data appears to be timed and designed to provide them with a mechanism to delay our COVID approval.
Where that argument falls apart is that we wouldn't have gotten phase 2 if the FDA wasn't satisfied with the safety of leronlimab. For a less visible disease they might have tried to pull a fast one. With the spotlight on Cytodyn after mild/moderate data release they wouldn't dare.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼